SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer

BACKGROUND: Combination of selumetinib plus docetaxel provided clinical benefit in a previous phase II trial for patients with KRAS-mutant advanced non-small-cell lung cancer (NSCLC). The phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria, J -C, Fülöp, A, Maciel, C, Fischer, J R, Girotto, G, Lago, S, Smit, E, Ostoros, G, Eberhardt, W E E, Lishkovska, P, Lovick, S, Mariani, G, McKeown, A, Kilgour, E, Smith, P, Bowen, K, Kohlmann, A, Carlile, D J, Jänne, P A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834012/
https://www.ncbi.nlm.nih.gov/pubmed/29045535
http://dx.doi.org/10.1093/annonc/mdx628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834012/
https://www.ncbi.nlm.nih.gov/pubmed/29045535
http://dx.doi.org/10.1093/annonc/mdx628

Ejemplares similares